Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,044 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Recruiting

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

NCT05272384

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +15 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Yale University New Haven, Connecticut, United States
View Trial Details
Recruiting

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

NCT03104491

Conditions
Acute Lymphocytic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • The University of Kansas Cancer Center Westwood, Kansas, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Nebraska Medical Center Omaha, Nebraska, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

NCT04269902

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 632 locations
View Trial Details
Recruiting

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

NCT04840602

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +18 more
Locations
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
View all 138 locations
View Trial Details
Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Local Institution - 0366 Los Alamitos, California, United States
  • Local Institution - 0272 San Diego, California, United States
  • Local Institution - 0273 West Hollywood, California, United States
  • Local Institution - 0381 Aurora, Colorado, United States
View all 266 locations
View Trial Details

Related conditions